Aclipse Therapeutics develops disease-modifying drug candidates targeting neuromuscular diseases by utilizing genomic, proteomic, and biomarker data to identify molecular pathways involved in inflammation and protein misfolding. Their lead candidates, M107 for gastroparesis and M102 for ALS, aim to improve patient outcomes by addressing the underlying pathologies of these severe conditions.
Funding
$10.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neuromuscular diseases like gastroparesis and amyotrophic lateral sclerosis (ALS) are debilitating conditions with limited treatment options that address the underlying disease mechanisms. Current therapies often fail to adequately target the complex molecular pathways involved in inflammation, cellular stress, and protein misfolding, leading to suboptimal patient outcomes. Effective treatments are needed to modify the disease course and improve the quality of life for individuals affected by these severe conditions.
Solution
Aclipse Therapeutics is developing disease-modifying drug candidates for neuromuscular diseases by targeting key molecular pathways involved in inflammation and protein misfolding. Their lead candidate, M107, aims to treat gastroparesis by modulating macrophage polarization to reduce inflammation and promote stomach function. The company's other lead candidate, M102, is being developed for ALS and employs a broad mechanistic approach by activating NRF2 and HSF1 pathways to combat oxidative stress, neuro-inflammation, mitochondrial dysfunction, and protein misfolding. Aclipse Therapeutics is also developing patient stratification approaches to identify potential drug responders and improve clinical outcomes.
Target Audience
The primary target audience includes patients suffering from gastroparesis and amyotrophic lateral sclerosis (ALS), as well as the healthcare providers who treat these conditions, and clinical researchers focused on neuromuscular diseases.
Features
- M107: Modulates macrophage polarization to switch pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages in the stomach.
- M107: Increases the population of interstitial cells of Cajal (the pacemaker cells of the stomach).
- M107: Decreases fibrosis of the stomach pylorus.
- M102: Dual activation of NRF2 and HSF1 pathways.
- M102: Targets multiple ALS pathomechanisms including oxidative stress, neuro-inflammation, mitochondrial dysfunction, and protein misfolding.
- Patient stratification approaches for sporadic ALS patients to improve clinical outcomes.